Form 4: Korro Bio CFO Acquires 30,000 Stock Options

Vineet Agarwal, CFO of Korro Bio, Inc., reports the acquisition of 30,000 stock options on February 3, 2025.

Summary

• On February 5, 2025, Vineet Agarwal, the Chief Financial Officer of Korro Bio, Inc. (KRRO), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on February 3, 2025, where Agarwal acquired 30,000 stock options.
• These options have an exercise price of $33.50.
• The options vest in 48 equal monthly installments starting February 3, 2025, contingent upon Agarwal's continued service.
• The options expire on February 2, 2035.
• Following the reported transaction, Agarwal directly owns 30,000 derivative securities.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a transaction. However, the granting of stock options to a key executive is generally viewed positively as it aligns their interests with shareholders.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options (48 months) suggests a long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use stock options to incentivize their executives.
• The vesting schedule of 48 months is also standard practice to ensure long-term commitment.

Stakeholder Impact

• The acquisition of stock options by the CFO could positively influence shareholder sentiment.

Key Dates